SSY Group Limited (02005.HK): Ziprasidone Hydrochloride API Approved for Marketing
NewTimeSpace News: On 7 August 2026, SSY Group Limited (02005.HK) announced that its ziprasidone hydrochloride has obtained registration approval from the NMPA as an active pharmaceutical ingredient for use in marketed pharmaceutical preparations.
According to the announcement, ziprasidone hydrochloride is a new atypical broad-spectrum antipsychotic agent belonging to the second generation of antipsychotics, mainly indicated for the treatment of schizophrenia.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY Group Limited(02005.HK): Methocarbamol Tablets Approved for Marketing; Phloroglucinol API Granted Registration
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
- Global X K-Pop and Culture ETF (03158.HK) Rises 3.37%, NAV at HKD 53.468
